Table 1.

Incidence of ocular treatment-emergent adverse events (safety population)

	Latanoprostene bunod 0.024% (N = 24)
	Study eye	Treated fellow eye
Total number of ocular TEAEs	28	27
Subjects with ≥1 TEAE, n (%)	21 (87.5)	21 (87.5)
Eye disordersa, n (% of subjects)
Conjunctival hyperaemia	12 (50.0)	12 (50.0)
Punctate keratitis	13 (54.2)	12 (50.0)
Conjunctival disorder	1 (4.2)	1 (4.2)
Eye pain	1 (4.2)	1 (4.2)
Visual acuity reduced	1 (4.2)	1 (4.2)

All subjects who received at least one dose of study drug

TEAE treatment-emergent adverse event

^aSystem organ class preferred terms